keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28426906/measuring-the-impact-of-dermatological-conditions-on-family-and-caregivers-a-review-of-dermatology-specific-instruments
#1
REVIEW
F Sampogna, A Y Finlay, S S Salek, P Chernyshov, F J Dalgard, A W M Evers, D Linder, L Manolache, S E Marron, F Poot, S Spillekom-van Koulil, Å Svensson, J C Szepietowski, L Tomas-Aragones, D Abeni
The patient is the centre of a web of relationships and the impact of his/her disease on family members and caregivers must be taken into account. The aim of this study was to identify the specific instruments that measure the impact of a dermatological disease on the quality of life (QoL) of family members, by performing a systematic search of the literature. Fifteen papers were identified, describing the creation and validation of nine instruments. Four of them concerned atopic dermatitis (Dermatitis Family Index, DFI; Parents' Index QoL Atopic Dermatitis, PiQoL-AD; QoL in Primary Caregivers of children with Atopic Dermatitis, QPCAD; Childhood Atopic Dermatits Impact Scale, CADIS), two measured the impact of psoriasis in family members (Psoriasis Family Index, PFI; FamilyPso), one the impact of epidermolysis bullosa (Epidermolysis Bullosa Burden of Disease, EB-BoD), one of ichthyosis (Family Burden Ichthyosis, FBI), and one was generic for dermatological conditions (Family Dermatology Life Quality Index, FDLQI)...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28426138/incremental-burden-of-cardiovascular-comorbidity-and-psoriatic-arthritis-among-adults-with-moderate-to-severe-psoriasis-in-five-european-countries
#2
M Augustin, J Vietri, H Tian, I Gilloteau
BACKGROUND: Moderate-to-severe psoriasis is associated with reduced health-related quality of life (HRQoL). Individuals with psoriasis are at increased risk for other medical conditions, but little information quantifies the incremental burden of psoriasis-associated comorbidity among European adults, and data have generally been limited to clinical samples. OBJECTIVE: To quantify the incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in the general population of France, Germany, Italy, Spain, and the United Kingdom (EU5)...
April 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28421729/effects-of-tnf-%C3%AE-inhibitors-in-patients-with-psoriasis-and-metabolic-syndrome-a-preliminary-study
#3
Giulia Merlo, Emanuele Cozzani, Martina Burlando, Stefano Calvieri, Concetta Potenza, Luca Stingeni, Giorgio Filosa, Monica Pau, Marco Simonacci, Marzia Caproni, Aurora Parodi
BACKGROUND: Psoriasis is an inflammatory disease, that is increasingly being considered as a systemic disorder. Among associated comorbidities, metabolic syndrome plays an important role. The effects of biological therapies on metabolic syndrome is controversial. METHODS: Thirty-one psoriatic patients with metabolic syndrome, eligible to treatment with anti-TNFα agents, were enrolled. Metabolic parameters were measured during 4 subsequent visits, one every 40 to 60 days...
April 19, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28407292/internalized-stigma-in-psoriasis-a-multicenter-study
#4
Erkan Alpsoy, Mualla Polat, Bilge FettahlıoGlu-Karaman, Ayse Serap Karadag, Pelin Kartal-Durmazlar, Basak YalCın, Selma Emre, Didem Didar-Balcı, Asli Bilgic-Temel, Ercan Arca, Rafet Koca, Kamer Gunduz, Murat Borlu, Tulin Ergun, Seval Dogruk-Kacar, Ayca Cordan-Yazici, Pınar Dursun, Ozlem BilgiC, Serap Gunes-Bilgili, Neslihan Sendur, Ozge Baysal, Ibrahim Halil-Yavuz, Gizem Yagcioglu, Ertan Yilmaz, Ufuk Kavuzlu, Yesim Senol
Internalized stigma is the adoption of negative attitudes and stereotypes of the society regarding a person's illness. It causes decreased self-esteem and life-satisfaction, increased depression and suicidality, and difficulty in coping with the illness. The primary aim of this study was to investigate the internalized stigma state of psoriatic patients and to identify the factors influencing internalized stigma. The secondary aim was to identify the correlation of internalized stigma with quality of life and perceived health status...
April 13, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28403510/-new-to-me-changing-patient-understanding-of-psoriasis-and-identifying-mechanisms-of-change-the-pso-well-%C3%A2-patient-materials-mixed-methods-feasibility-study
#5
P A Nelson, K Kane, C J Pearce, C Bundy, A Chisholm, R Hilton, R Thorneloe, H Young, C E M Griffiths, L Cordingley
BACKGROUND: Psoriasis is an inflammatory, long-term condition (LTC) involving co-morbidities, unhealthy lifestyle and significant life impact. Patients' understanding of psoriasis is limited and support lacking. The Common-Sense Self-Regulatory Model emphasises the role of illness/treatment beliefs on coping/self-management. New 'Pso Well(®) ' patient materials informed by the model addressed: psoriasis as a LTC; medications management; and lifestyle behaviours. OBJECTIVES: To investigate whether Pso Well(®) materials: 1) broaden understanding of psoriasis without increasing anxiety; 2) are acceptable and; 3) comprise features that appear to effect change...
April 12, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28403245/author-paper-affiliation-network-architecture-influences-the-methodological-quality-of-systematic-reviews-and-meta-analyses-of-psoriasis
#6
Juan Luis Sanz-Cabanillas, Juan Ruano, Francisco Gomez-Garcia, Patricia Alcalde-Mellado, Jesus Gay-Mimbrera, Macarena Aguilar-Luque, Beatriz Maestre-Lopez, Marcelino Gonzalez-Padilla, Pedro J Carmona-Fernandez, Antonio Velez Garcia-Nieto, Beatriz Isla-Tejera
Moderate-to-severe psoriasis is associated with significant comorbidity, an impaired quality of life, and increased medical costs, including those associated with treatments. Systematic reviews (SRs) and meta-analyses (MAs) of randomized clinical trials are considered two of the best approaches to the summarization of high-quality evidence. However, methodological bias can reduce the validity of conclusions from these types of studies and subsequently impair the quality of decision making. As co-authorship is among the most well-documented forms of research collaboration, the present study aimed to explore whether authors' collaboration methods might influence the methodological quality of SRs and MAs of psoriasis...
2017: PloS One
https://www.readbyqxmd.com/read/28400641/secukinumab-first-in-class-interleukin-17a-inhibitor-for-the-treatment-of-psoriasis
#7
Kiran Godse
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28395376/-rehabilitation-of-children-and-adolescents-with-chronic-skin-diseases
#8
R Stachow, M Küppers-Chinnow, S Scheewe
Chronic skin diseases are a common indication for inpatient rehabilitation in children and adolescents. Atopic eczema and psoriasis play the most important role. But other rare congenital dermatoses such as ichthyoses or epidermolysis bullosa can also be rehabilitated. Patients with skin diseases are often considerably stigmatized and report a limited quality of life and participation. The somatic and psychosocial development of the children is also often severely affected by severe forms of the diseases. The concept of inpatient rehabilitation is, on the one hand, the development of an individually adapted topical therapy plan, which often follows a step concept and is adapted to the severity of the skin symptoms...
April 2017: Die Rehabilitation
https://www.readbyqxmd.com/read/28369707/comparative-effectiveness-of-biologic-therapies-on-improvements-in-quality-of-life-in-patients-with-psoriasis
#9
I Y K Iskandar, D M Ashcroft, R B Warren, M Lunt, K McElhone, C H Smith, N J Reynolds, C E M Griffiths
BACKGROUND: Evidence of the comparative effectiveness of biologic therapies for psoriasis on health related quality of life (HRQoL) in routine clinical practice is limited. OBJECTIVES: To examine the comparative effectiveness of adalimumab, etanercept and ustekinumab on HRQoL in psoriasis patients, and to identify potential predictors for improved HRQoL. METHOD: Prospective cohort study in which changes in HRQoL were assessed using the Dermatology Life Quality Index (DLQI) and EuroQoL-5D (EQ-5D) at 6 and 12 months...
March 30, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28352929/effectiveness-of-adalimumab-in-the-treatment-of-scalp-and-nail-affection-in-patients-with-moderate-to-severe-plaque-psoriasis-in-routine-clinical-practice
#10
Kuzma Khobzey, Iryna Liskova, Andrea Szegedi, Lev Pavlovsky, Tomaž Lunder, Külli Kingo, Jovan Miljković, Juraj Péč, Maša Bohinc, Maja Hojnik
INTRODUCTION: Data on the effectiveness of biologics in the treatment of nail and scalp psoriasis (PSO) in a routine clinical setting are scarce. The aim of this study was therefore to evaluate the effectiveness of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice. METHODS: Five hundred one patients were analyzed in this observational study; 157 patients had nail involvement (nail PSO set; NPS) and 404 had scalp involvement (scalp PSO set; SPS)...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28320215/correction-to-psoriasis-patients-with-psoriasis-area-and-severity-index-pasi-90-response-achieve-greater-health-related-quality-of-life-improvements-than-those-with-pasi-75-89-response-results-from-two-phase-3-studies-of-secukinumab
#11
https://www.readbyqxmd.com/read/28301043/a-topical-treatment-optimisation-programme-ttop-improves-clinical-outcome-to-calcipotriol-betamethasone-gel-in-psoriasis-results-of-the-64-week-multinational-randomized-phase-iv-study-in-1790-patients-pso-top
#12
K Reich, I Zschocke, H Bachelez, E M G J de Jong, P Gisondi, L Puig, R B Warren, C Ortland, U Mrowietz
BACKGROUND: Around two-thirds of psoriasis patients do not adhere to topical treatment. The 'Topical Treatment Optimisation Programme' (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/email helpdesks and treatment reminders. It has been developed by patients and dermatologists to help increase adherence in psoriasis. OBJECTIVE: To compare TTOP with standard of care ('non-TTOP') within a large European investigator-initiated study, PSO-TOP (Clinicaltrials...
March 16, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28300857/evaluation-of-the-physician-global-assessment-and-body-surface-area-composite-tool-for-assessing-psoriasis-response-to-apremilast-therapy-results-from-esteem-1-and-esteem-2
#13
Kristina C Duffin, Kim A Papp, Jerry Bagel, Eugenia Levi, Rongdean Chen, Alice B Gottlieb
BACKGROUND: The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE: To evaluate the product of PGAxBSA as a sensitive alternative to the Psoriasis Area and Severity Index (PASI) for assessing disease severity and therapeutic response with data collected from the phase 3 ESTEEM 1 and 2 trials. METHODS: This post hoc analysis included 836 patients randomized to apremilast 30 mg BID at baseline (ESTEEM 1, n=562; ESTEEM 2, n=274)...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28300302/quality-of-life-instruments-in-psoriasis-clinical-trials
#14
D Kivelevitch, P Michel, A Menter
No abstract text is available yet for this article.
March 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28294430/rapid-improvements-in-health-related-quality-of-life-and-itch-with-ixekizumab-treatment-in-randomized-phase-3-trials-results-from-uncover-2-and-uncover-3
#15
C L Leonardi, A Blauvelt, H L Sofen, M Gooderham, M Augustin, R Burge, B Zhu, K Reich
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post-hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly, or placebo (PBO) for 12 weeks...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28291975/quality-of-life-of-persons-suffering-from-schizophrenia-psoriasis-and-physical-disabilities
#16
Tija Žarković Palijan, Dražen Kovačević, Mirela Vlastelica, Elizabeta Dadić-Hero, Marijana Sarilar
BACKGROUND: Studies have addressed the impact of chronic diseases and their treatment on quality of life (Qol), but the relative impact of different chronic conditions on patients' level of subjective functioning is mostly unknown. Stigma is associated with poor Qol in various chronic diseases. The aim of this study was to compare the quality of life of people suffering from schizophrenia with the quality of life of patients with psoriasis and physical disabilities. SUBJECTS AND METHODS: Study was conducted on a sample of 88 persons suffering from schizophrenia, 60 persons with physical disabilities and 57 persons with psoriasis...
March 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28290219/2-crisaborole-topical-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis
#17
Alice C Cheape, Dedee F Murrell
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle...
April 5, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28281329/addiction-an-underestimated-problem-in-psoriasis-health-care
#18
A Zink, M Herrmann, T Fischer, F Lauffer, N Garzorz-Stark, A Böhner, C D Spinner, T Biedermann, K Eyerich
BACKGROUND: Psoriasis is a disease of enormous socio-economic impact. Despite approval of numerous highly efficient and costly therapies, a minor proportion of severely affected patients actually receives sufficient treatment. OBJECTIVE: To investigate whether addictions are associated with psoriasis and to develop evidence-based recommendations for dermatologists in their daily clinical practice in order to improve medical assessment of psoriasis and patients' quality of life...
March 9, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28273375/characteristics-of-patients-receiving-ustekinumab-compared-with-secukinumab-for-treatment-of-moderate-to-severe-plaque-psoriasis-nationwide-results-from-the-dermbio-registry
#19
A Egeberg, L Iversen, R Gniadecki, L Hvid, T N Dam, L E Bryld, L Skov
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. OBJECTIVE: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. METHODS: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28271561/a-european-subset-analysis-from-the-population-based-multinational-assessment-of-psoriasis-and-psoriatic-arthritis-mapp-shows-country-specific-features-results-from-psoriasis-patients-in-spain
#20
L Puig, P C M van de Kerkhof, K Reich, H Bachelez, J Barker, G Girolomoni, C F Paul
BACKGROUND: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). OBJECTIVE: Utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). METHODS: MAPP was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n=349), Germany (n=311), Italy (n=359), Spain (n=354) and the United Kingdom (n=327)...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"